biote (BTMD) AI Stock Analysis

• Market Cap: $180.00M
• Dividend Yield: N/A
• Average Volume (3M): 265.59K
• Price to Earnings (P/E): 18.0
• Beta (1Y): 1.00
• Revenue Growth: 6.38%
• EPS Growth: N/A
• Country: US
• Employees: 217
• Sector: Healthcare
• Sector Strength: 77
• Industry: Medical - Care Facilities
• EPS (TTM): 0.18
• Shares Outstanding: 33,073,277
• 10 Day Avg. Volume: 182,858
• 30 Day Avg. Volume: 265,592
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 1.07
• Price to Cash Flow (P/CF): 4.30
• P/FCF Ratio: 4.70
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $7.50
• Price Target Upside: 130.77% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

The company's overall stock score reflects solid revenue growth and efficient cash flow management, offset by high leverage and negative equity. Technical indicators suggest bearish momentum, while the valuation is moderate with a fair P/E ratio. The earnings call provided positive guidance for 2025, though challenges such as increased expenses and slowed customer growth remain. Strategic initiatives may improve financial stability and market position if successfully implemented.

Positive Factors

Leadership strategy

With the new CEO at the helm, BTMD will focus on refining execution around creating higher efficiency with existing clinics and acquiring/onboarding new clinics.

Market opportunity

The market opportunity remains attractive and the end consumer remains loyal to BTMD's products even in a choppy macro backdrop.

Negative Factors

Sales force allocation

New clinic growth suffered during the quarter as the sales force was dedicated to top-tier clinics to smooth the transition to the new software.

Software transition

Ongoing software transition issues will linger, and it will likely take 2+ quarters for trends to start to show improvement.

biote Business Overview & Revenue Model

Company Description

Biote (BTMD) is a healthcare company operating in the biotechnology sector, primarily focused on providing hormone optimization treatments. The company develops and offers hormone replacement therapies, particularly targeting age-related conditions, to enhance the quality of life for individuals experiencing hormonal imbalances. Biote utilizes a network of certified practitioners who deliver its proprietary hormone optimization solutions to patients.

How the Company Makes Money

Biote makes money through the sale of its hormone optimization therapies and related medical products. The company's revenue model primarily involves partnerships with healthcare practitioners who are certified to administer Biote's treatments. These practitioners purchase Biote's products and services, which are then provided to patients, generating revenue for the company. Additionally, Biote may engage in training and certification programs for medical professionals, contributing to its earnings. Significant partnerships with healthcare providers and clinics help expand its market reach, further driving revenue growth.

biote Financial Statement Overview

Summary

The company shows strong revenue growth and efficient cash flow management, but financial health is hampered by high leverage and negative equity. Profitability remains a challenge, with efforts needed to improve equity and reduce debt.

Income Statement

The company has shown consistent revenue growth over the years, with a notable increase from 2023 to 2024. The gross profit margin remains strong, highlighting efficient cost management. However, the net profit margin is quite low, indicating challenges in translating revenue growth into substantial net profits. Additionally, EBIT and EBITDA margins show moderate improvement, but there is room for further operational efficiency.

Balance Sheet

The company's balance sheet reflects high leverage, as indicated by a negative stockholders' equity, which is a significant risk factor. The debt-to-equity ratio is unfavorable due to negative equity. Despite these concerns, the company maintains a reasonable equity ratio and positive total assets, which could stabilize with improved equity management.

Cash Flow

Cash flow analysis shows a robust operating cash flow with significant improvement in free cash flow over the years, especially from 2023 to 2024. The operating cash flow to net income ratio is healthy, indicating strong cash generation relative to net income. The free cash flow to net income ratio supports the sustainability of cash flows for future investments and debt servicing.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
193.06M	197.19M	185.36M	164.96M	139.40M	116.57M
	Gross Profit
132.97M	139.06M	127.48M	110.38M	90.58M	71.64M
	EBIT
38.91M	31.61M	28.66M	-60.72M	34.56M	31.78M
	EBITDA
16.81M	31.61M	9.23M	9.24M	35.98M	32.91M
	Net Income Common Stockholders
10.04M	3.16M	3.32M	1.32M	32.62M	29.16M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
89.00M	39.34M	89.00M	79.23M	26.77M	17.21M
	Total Assets
155.29M	122.37M	155.29M	111.64M	54.33M	32.59M
	Total Debt
114.87M	9.66M	114.87M	120.43M	37.34M	42.35M
	Net Debt
25.87M	-29.68M	25.87M	41.20M	10.57M	25.15M
	Total Liabilities
191.84M	224.57M	191.84M	169.92M	50.20M	49.66M
	Stockholders Equity
-29.40M	-102.20M	-29.40M	-44.46M	4.13M	-17.07M
Cash Flow		Free Cash Flow
32.95M	38.81M	24.17M	-10.99M	29.91M	25.03M
	Operating Cash Flow
39.83M	45.24M	26.88M	-9.16M	33.72M	26.43M
	Investing Cash Flow
1.51M	-18.80M	-2.71M	-1.84M	-3.81M	-1.39M
	Financing Cash Flow
-68.67M	-76.08M	-14.38M	63.46M	-20.34M	-18.32M

biote Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BTMD, the sentiment is Negative. The current price of 3.25 is below the 20-day moving average (MA) of 3.71, below the 50-day MA of 4.33, and below the 200-day MA of 5.76, indicating a bearish trend. The MACD of -0.27 indicates Positive momentum. The RSI at 41.60 is Neutral, neither overbought nor oversold. The STOCH value of 14.93 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BTMD.

biote Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HIMS	71 Outperform	$5.77B	51.93	30.71%	―	69.33%	―
BTMD	58 Neutral	$180.00M	18.05	-7.92%	―	6.38%	―
EXAS	53 Neutral	$7.90B	―	-37.09%	―	10.37%	-389.98%
MYGN	51 Neutral	$742.34M	―	-17.15%	―	12.15%	61.33%
GH	49 Neutral	$5.01B	―	-4584.47%	―	31.04%	16.91%
Sector *	48 Neutral	$6.35B	1.19	-46.87%	2.63%	17.16%	1.34%
QDEL	46 Neutral	$1.90B	―	-50.74%	―	-7.03%	-20233.78%

biote Corporate Events

Biote Releases Updated Investor Presentation for 2025

On March 17, 2025, Biote Corp. released an updated Investor Presentation on its website, outlining its financial performance and strategic positioning. The presentation highlighted Biote’s leadership in hormone optimization, with significant revenue and adjusted EBITDA figures for 2024, emphasizing its role as a trusted provider in a growing market. The company’s strategic focus includes expanding its practitioner network and enhancing its comprehensive healthcare approach, which could strengthen its market position and impact stakeholders positively.

Biote Announces CEO Transition Effective February 2025

On January 30, 2025, Biote Corp. announced the retirement of CEO Terry Weber, effective February 1, 2025, who will transition to a strategic advisor role. Bret Christensen, an experienced executive in women’s health and the broader healthcare sector, will succeed Weber as CEO and Director, bringing his extensive expertise to drive Biote’s growth and value creation for stakeholders.